APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-oncology Biopharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Industry Research

Non-oncology Biopharmaceuticals Industry Research Report 2026

20 December 2025142 pages

Choose your research edition.

Industry ResearchNon-oncology Biopharmaceuticals Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-oncology Biopharmaceuticals Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Non-oncology Biopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-oncology Biopharmaceuticals Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-oncology Biopharmaceuticals Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The global Non-oncology Biopharmaceuticals market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Non-oncology Biopharmaceuticals market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Non-oncology Biopharmaceuticals market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Non-oncology Biopharmaceuticals market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Non-oncology Biopharmaceuticals include Takeda, Teva, Sanofi, Johnson & Johnson, Novartis, Novo Nordisk, Merck, Mylan and Roche, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Non-oncology Biopharmaceuticals market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Non-oncology Biopharmaceuticals.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Non-oncology Biopharmaceuticals Market by Company

Takeda

Teva

Sanofi

Johnson & Johnson

Novartis

Novo Nordisk

Merck

Mylan

Roche

Eli Lilly

Pfizer

GlaxoSmithKline

Biogen

Amgen

AbbVie

AstraZeneca

UCB Pharma

Swedish Orphan Biovitrum

LEO Pharma

Elusys Therapeutics

Bristol-Myers Squibb

Boehringer Ingelheim

Alexion Pharmaceuticals

Non-oncology Biopharmaceuticals Segment by Type

Biologics

Biosimilars

Non-oncology Biopharmaceuticals Segment by Application

Immunology

Endocrinology

Others

Non-oncology Biopharmaceuticals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-oncology Biopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-oncology Biopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-oncology Biopharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Non-oncology Biopharmaceuticals companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Non-oncology Biopharmaceuticals Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2021-2026) Table 7. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type (2027-2032) Table 9. Global Non-oncology Biopharmaceuticals Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2021-2026) Table 11. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2027-2032) Table 13. Global Non-oncology Biopharmaceuticals Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Non-oncology Biopharmaceuticals Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Non-oncology Biopharmaceuticals Market Share by Region (2021-2026) Table 16. Global Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Non-oncology Biopharmaceuticals Market Share by Region (2027-2032) Table 18. Non-oncology Biopharmaceuticals Industry Trends Table 19. Non-oncology Biopharmaceuticals Industry Drivers Table 20. Non-oncology Biopharmaceuticals Industry Opportunities and Challenges Table 21. Non-oncology Biopharmaceuticals Market Restraints Table 22. Global Top Non-oncology Biopharmaceuticals Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2021-2026) Table 24. Global Non-oncology Biopharmaceuticals Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Non-oncology Biopharmaceuticals, Headquarters and Area Served Table 26. Global Non-oncology Biopharmaceuticals Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Non-oncology Biopharmaceuticals by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Non-oncology Biopharmaceuticals Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Non-oncology Biopharmaceuticals Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Non-oncology Biopharmaceuticals Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Non-oncology Biopharmaceuticals Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Non-oncology Biopharmaceuticals Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Non-oncology Biopharmaceuticals Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Non-oncology Biopharmaceuticals Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Non-oncology Biopharmaceuticals Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2027-2032) & (US$ Million) Table 45. Takeda Company Information Table 46. Takeda Business Overview Table 47. Takeda Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 48. Takeda Non-oncology Biopharmaceuticals Product Portfolio Table 49. Takeda Recent Developments Table 50. Teva Company Information Table 51. Teva Business Overview Table 52. Teva Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 53. Teva Non-oncology Biopharmaceuticals Product Portfolio Table 54. Teva Recent Developments Table 55. Sanofi Company Information Table 56. Sanofi Business Overview Table 57. Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 58. Sanofi Non-oncology Biopharmaceuticals Product Portfolio Table 59. Sanofi Recent Developments Table 60. Johnson & Johnson Company Information Table 61. Johnson & Johnson Business Overview Table 62. Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 63. Johnson & Johnson Non-oncology Biopharmaceuticals Product Portfolio Table 64. Johnson & Johnson Recent Developments Table 65. Novartis Company Information Table 66. Novartis Business Overview Table 67. Novartis Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 68. Novartis Non-oncology Biopharmaceuticals Product Portfolio Table 69. Novartis Recent Developments Table 70. Novo Nordisk Company Information Table 71. Novo Nordisk Business Overview Table 72. Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 73. Novo Nordisk Non-oncology Biopharmaceuticals Product Portfolio Table 74. Novo Nordisk Recent Developments Table 75. Merck Company Information Table 76. Merck Business Overview Table 77. Merck Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 78. Merck Non-oncology Biopharmaceuticals Product Portfolio Table 79. Merck Recent Developments Table 80. Mylan Company Information Table 81. Mylan Business Overview Table 82. Mylan Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 83. Mylan Non-oncology Biopharmaceuticals Product Portfolio Table 84. Mylan Recent Developments Table 85. Roche Company Information Table 86. Roche Business Overview Table 87. Roche Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 88. Roche Non-oncology Biopharmaceuticals Product Portfolio Table 89. Roche Recent Developments Table 90. Eli Lilly Company Information Table 91. Eli Lilly Business Overview Table 92. Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 93. Eli Lilly Non-oncology Biopharmaceuticals Product Portfolio Table 94. Eli Lilly Recent Developments Table 95. Pfizer Company Information Table 96. Pfizer Business Overview Table 97. Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 98. Pfizer Non-oncology Biopharmaceuticals Product Portfolio Table 99. Pfizer Recent Developments Table 100. GlaxoSmithKline Company Information Table 101. GlaxoSmithKline Business Overview Table 102. GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 103. GlaxoSmithKline Non-oncology Biopharmaceuticals Product Portfolio Table 104. GlaxoSmithKline Recent Developments Table 105. Biogen Company Information Table 106. Biogen Business Overview Table 107. Biogen Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 108. Biogen Non-oncology Biopharmaceuticals Product Portfolio Table 109. Biogen Recent Developments Table 110. Amgen Company Information Table 111. Amgen Business Overview Table 112. Amgen Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 113. Amgen Non-oncology Biopharmaceuticals Product Portfolio Table 114. Amgen Recent Developments Table 115. AbbVie Company Information Table 116. AbbVie Business Overview Table 117. AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 118. AbbVie Non-oncology Biopharmaceuticals Product Portfolio Table 119. AbbVie Recent Developments Table 120. AstraZeneca Company Information Table 121. AstraZeneca Business Overview Table 122. AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 123. AstraZeneca Non-oncology Biopharmaceuticals Product Portfolio Table 124. AstraZeneca Recent Developments Table 125. UCB Pharma Company Information Table 126. UCB Pharma Business Overview Table 127. UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 128. UCB Pharma Non-oncology Biopharmaceuticals Product Portfolio Table 129. UCB Pharma Recent Developments Table 130. Swedish Orphan Biovitrum Company Information Table 131. Swedish Orphan Biovitrum Business Overview Table 132. Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 133. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product Portfolio Table 134. Swedish Orphan Biovitrum Recent Developments Table 135. LEO Pharma Company Information Table 136. LEO Pharma Business Overview Table 137. LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 138. LEO Pharma Non-oncology Biopharmaceuticals Product Portfolio Table 139. LEO Pharma Recent Developments Table 140. Elusys Therapeutics Company Information Table 141. Elusys Therapeutics Business Overview Table 142. Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 143. Elusys Therapeutics Non-oncology Biopharmaceuticals Product Portfolio Table 144. Elusys Therapeutics Recent Developments Table 145. Bristol-Myers Squibb Company Information Table 146. Bristol-Myers Squibb Business Overview Table 147. Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 148. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product Portfolio Table 149. Bristol-Myers Squibb Recent Developments Table 150. Boehringer Ingelheim Company Information Table 151. Boehringer Ingelheim Business Overview Table 152. Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 153. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product Portfolio Table 154. Boehringer Ingelheim Recent Developments Table 155. Alexion Pharmaceuticals Company Information Table 156. Alexion Pharmaceuticals Business Overview Table 157. Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2021-2026) & (US$ Million) Table 158. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product Portfolio Table 159. Alexion Pharmaceuticals Recent Developments Table 160. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Non-oncology Biopharmaceuticals Product Image Figure 5. Global Non-oncology Biopharmaceuticals Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Non-oncology Biopharmaceuticals Market Share by Type: 2025 VS 2032 Figure 7. Biologics Product Figure 8. Biosimilars Product Figure 9. Global Non-oncology Biopharmaceuticals Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Non-oncology Biopharmaceuticals Market Share by Application: 2025 VS 2032 Figure 11. Immunology Product Figure 12. Endocrinology Product Figure 13. Others Product Figure 14. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 15. Global Non-oncology Biopharmaceuticals Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Non-oncology Biopharmaceuticals Market Share by Region: 2025 VS 2032 Figure 17. Global Non-oncology Biopharmaceuticals Market Share by Players in 2025 Figure 18. Global Non-oncology Biopharmaceuticals Manufacturers Established Date Figure 19. Global Top 5 and 10 Non-oncology Biopharmaceuticals Players Market Share by Revenue in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. North America Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Non-oncology Biopharmaceuticals Market Share by Country (2021-2032) Figure 23. United States Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Canada Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Mexico Non-oncology Biopharmaceuticals Market Share by Country (2021-2032) Figure 26. Europe Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Europe Non-oncology Biopharmaceuticals Market Share by Country (2021-2032) Figure 28. Germany Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. France Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. U.K. Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Italy Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Spain Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Russia Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Netherlands Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Nordic Countries Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Country (2021-2032) Figure 38. China Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Japan Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. South Korea Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. India Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. India Non-oncology Biopharmaceuticals Market Share by Country (2021-2032) Figure 43. Australia Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. China Taiwan Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. Southeast Asia Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. South America Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. South America Non-oncology Biopharmaceuticals Market Share by Country (2021-2032) Figure 48. Brazil Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. Argentina Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Chile Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Colombia Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Peru Non-oncology Biopharmaceuticals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Takeda Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 54. Teva Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 55. Sanofi Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 56. Johnson & Johnson Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 57. Novartis Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 58. Novo Nordisk Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 59. Merck Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 60. Mylan Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 61. Roche Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 62. Eli Lilly Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 63. Pfizer Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 64. GlaxoSmithKline Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 65. Biogen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 66. Amgen Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 67. AbbVie Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 68. AstraZeneca Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 69. UCB Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 70. Swedish Orphan Biovitrum Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 71. LEO Pharma Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 72. Elusys Therapeutics Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 73. Bristol-Myers Squibb Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 74. Boehringer Ingelheim Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026) Figure 75. Alexion Pharmaceuticals Revenue Growth Rate in Non-oncology Biopharmaceuticals Business (2021-2026)

Scope & coverage.

Types
  • Biologics
  • Biosimilars
Applications
  • Immunology
  • Endocrinology
  • Others
Companies covered
  • Takeda
  • Teva
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Novo Nordisk
  • Merck
  • Mylan
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Amgen
  • AbbVie
  • AstraZeneca
  • UCB Pharma
  • Swedish Orphan Biovitrum
  • LEO Pharma
  • Elusys Therapeutics
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Alexion Pharmaceuticals

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Non-oncology Biopharmaceuticals by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Biologics
  5. 2.2.3 Biosimilars
  6. 2.3 Non-oncology Biopharmaceuticals by Application
  7. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  8. 2.3.2 Immunology
  9. 2.3.3 Endocrinology
  10. 2.3.4 Others
  11. 2.4 Assumptions and Limitations
3 Non-oncology Biopharmaceuticals Breakdown Data by Type
  1. 3.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2021-2026)
  2. 3.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2027-2032)
4 Non-oncology Biopharmaceuticals Breakdown Data by Application
  1. 4.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Application (2021-2026)
  2. 4.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Non-oncology Biopharmaceuticals Market Perspective (2021-2032)
  2. 5.2 Global Non-oncology Biopharmaceuticals Growth Trends by Region
  3. 5.2.1 Global Non-oncology Biopharmaceuticals Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Non-oncology Biopharmaceuticals Historic Market Size by Region (2021-2026)
  5. 5.2.3 Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2027-2032)
  6. 5.3 Non-oncology Biopharmaceuticals Market Dynamics
  7. 5.3.1 Non-oncology Biopharmaceuticals Industry Trends
  8. 5.3.2 Non-oncology Biopharmaceuticals Market Drivers
  9. 5.3.3 Non-oncology Biopharmaceuticals Market Challenges
  10. 5.3.4 Non-oncology Biopharmaceuticals Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue
  2. 6.1.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue (2021-2026)
  3. 6.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Non-oncology Biopharmaceuticals Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Non-oncology Biopharmaceuticals Head Office and Area Served
  6. 6.4 Global Non-oncology Biopharmaceuticals Players, Product Type & Application
  7. 6.5 Global Non-oncology Biopharmaceuticals Manufacturers Established Date
  8. 6.6 Global Non-oncology Biopharmaceuticals Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Non-oncology Biopharmaceuticals Market Size (2021-2032)
  2. 7.2 North America Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Non-oncology Biopharmaceuticals Market Size by Country (2021-2026)
  4. 7.4 North America Non-oncology Biopharmaceuticals Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Non-oncology Biopharmaceuticals Market Size (2021-2032)
  2. 8.2 Europe Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Non-oncology Biopharmaceuticals Market Size by Country (2021-2026)
  4. 8.4 Europe Non-oncology Biopharmaceuticals Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size (2021-2032)
  2. 9.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Non-oncology Biopharmaceuticals Market Size (2021-2032)
  2. 10.2 South America Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Non-oncology Biopharmaceuticals Market Size by Country (2021-2026)
  4. 10.4 South America Non-oncology Biopharmaceuticals Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size (2021-2032)
  2. 11.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Takeda
  2. 12.1.1 Takeda Company Information
  3. 12.1.2 Takeda Business Overview
  4. 12.1.3 Takeda Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  5. 12.1.4 Takeda Non-oncology Biopharmaceuticals Product Portfolio
  6. 12.1.5 Takeda Recent Developments
  7. 12.2 Teva
  8. 12.2.1 Teva Company Information
  9. 12.2.2 Teva Business Overview
  10. 12.2.3 Teva Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  11. 12.2.4 Teva Non-oncology Biopharmaceuticals Product Portfolio
  12. 12.2.5 Teva Recent Developments
  13. 12.3 Sanofi
  14. 12.3.1 Sanofi Company Information
  15. 12.3.2 Sanofi Business Overview
  16. 12.3.3 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  17. 12.3.4 Sanofi Non-oncology Biopharmaceuticals Product Portfolio
  18. 12.3.5 Sanofi Recent Developments
  19. 12.4 Johnson & Johnson
  20. 12.4.1 Johnson & Johnson Company Information
  21. 12.4.2 Johnson & Johnson Business Overview
  22. 12.4.3 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  23. 12.4.4 Johnson & Johnson Non-oncology Biopharmaceuticals Product Portfolio
  24. 12.4.5 Johnson & Johnson Recent Developments
  25. 12.5 Novartis
  26. 12.5.1 Novartis Company Information
  27. 12.5.2 Novartis Business Overview
  28. 12.5.3 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  29. 12.5.4 Novartis Non-oncology Biopharmaceuticals Product Portfolio
  30. 12.5.5 Novartis Recent Developments
  31. 12.6 Novo Nordisk
  32. 12.6.1 Novo Nordisk Company Information
  33. 12.6.2 Novo Nordisk Business Overview
  34. 12.6.3 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  35. 12.6.4 Novo Nordisk Non-oncology Biopharmaceuticals Product Portfolio
  36. 12.6.5 Novo Nordisk Recent Developments
  37. 12.7 Merck
  38. 12.7.1 Merck Company Information
  39. 12.7.2 Merck Business Overview
  40. 12.7.3 Merck Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  41. 12.7.4 Merck Non-oncology Biopharmaceuticals Product Portfolio
  42. 12.7.5 Merck Recent Developments
  43. 12.8 Mylan
  44. 12.8.1 Mylan Company Information
  45. 12.8.2 Mylan Business Overview
  46. 12.8.3 Mylan Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  47. 12.8.4 Mylan Non-oncology Biopharmaceuticals Product Portfolio
  48. 12.8.5 Mylan Recent Developments
  49. 12.9 Roche
  50. 12.9.1 Roche Company Information
  51. 12.9.2 Roche Business Overview
  52. 12.9.3 Roche Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  53. 12.9.4 Roche Non-oncology Biopharmaceuticals Product Portfolio
  54. 12.9.5 Roche Recent Developments
  55. 12.10 Eli Lilly
  56. 12.10.1 Eli Lilly Company Information
  57. 12.10.2 Eli Lilly Business Overview
  58. 12.10.3 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  59. 12.10.4 Eli Lilly Non-oncology Biopharmaceuticals Product Portfolio
  60. 12.10.5 Eli Lilly Recent Developments
  61. 12.11 Pfizer
  62. 12.11.1 Pfizer Company Information
  63. 12.11.2 Pfizer Business Overview
  64. 12.11.3 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  65. 12.11.4 Pfizer Non-oncology Biopharmaceuticals Product Portfolio
  66. 12.11.5 Pfizer Recent Developments
  67. 12.12 GlaxoSmithKline
  68. 12.12.1 GlaxoSmithKline Company Information
  69. 12.12.2 GlaxoSmithKline Business Overview
  70. 12.12.3 GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  71. 12.12.4 GlaxoSmithKline Non-oncology Biopharmaceuticals Product Portfolio
  72. 12.12.5 GlaxoSmithKline Recent Developments
  73. 12.13 Biogen
  74. 12.13.1 Biogen Company Information
  75. 12.13.2 Biogen Business Overview
  76. 12.13.3 Biogen Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  77. 12.13.4 Biogen Non-oncology Biopharmaceuticals Product Portfolio
  78. 12.13.5 Biogen Recent Developments
  79. 12.14 Amgen
  80. 12.14.1 Amgen Company Information
  81. 12.14.2 Amgen Business Overview
  82. 12.14.3 Amgen Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  83. 12.14.4 Amgen Non-oncology Biopharmaceuticals Product Portfolio
  84. 12.14.5 Amgen Recent Developments
  85. 12.15 AbbVie
  86. 12.15.1 AbbVie Company Information
  87. 12.15.2 AbbVie Business Overview
  88. 12.15.3 AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  89. 12.15.4 AbbVie Non-oncology Biopharmaceuticals Product Portfolio
  90. 12.15.5 AbbVie Recent Developments
  91. 12.16 AstraZeneca
  92. 12.16.1 AstraZeneca Company Information
  93. 12.16.2 AstraZeneca Business Overview
  94. 12.16.3 AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  95. 12.16.4 AstraZeneca Non-oncology Biopharmaceuticals Product Portfolio
  96. 12.16.5 AstraZeneca Recent Developments
  97. 12.17 UCB Pharma
  98. 12.17.1 UCB Pharma Company Information
  99. 12.17.2 UCB Pharma Business Overview
  100. 12.17.3 UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  101. 12.17.4 UCB Pharma Non-oncology Biopharmaceuticals Product Portfolio
  102. 12.17.5 UCB Pharma Recent Developments
  103. 12.18 Swedish Orphan Biovitrum
  104. 12.18.1 Swedish Orphan Biovitrum Company Information
  105. 12.18.2 Swedish Orphan Biovitrum Business Overview
  106. 12.18.3 Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  107. 12.18.4 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product Portfolio
  108. 12.18.5 Swedish Orphan Biovitrum Recent Developments
  109. 12.19 LEO Pharma
  110. 12.19.1 LEO Pharma Company Information
  111. 12.19.2 LEO Pharma Business Overview
  112. 12.19.3 LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  113. 12.19.4 LEO Pharma Non-oncology Biopharmaceuticals Product Portfolio
  114. 12.19.5 LEO Pharma Recent Developments
  115. 12.20 Elusys Therapeutics
  116. 12.20.1 Elusys Therapeutics Company Information
  117. 12.20.2 Elusys Therapeutics Business Overview
  118. 12.20.3 Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  119. 12.20.4 Elusys Therapeutics Non-oncology Biopharmaceuticals Product Portfolio
  120. 12.20.5 Elusys Therapeutics Recent Developments
  121. 12.21 Bristol-Myers Squibb
  122. 12.21.1 Bristol-Myers Squibb Company Information
  123. 12.21.2 Bristol-Myers Squibb Business Overview
  124. 12.21.3 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  125. 12.21.4 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product Portfolio
  126. 12.21.5 Bristol-Myers Squibb Recent Developments
  127. 12.22 Boehringer Ingelheim
  128. 12.22.1 Boehringer Ingelheim Company Information
  129. 12.22.2 Boehringer Ingelheim Business Overview
  130. 12.22.3 Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  131. 12.22.4 Boehringer Ingelheim Non-oncology Biopharmaceuticals Product Portfolio
  132. 12.22.5 Boehringer Ingelheim Recent Developments
  133. 12.23 Alexion Pharmaceuticals
  134. 12.23.1 Alexion Pharmaceuticals Company Information
  135. 12.23.2 Alexion Pharmaceuticals Business Overview
  136. 12.23.3 Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2021-2026)
  137. 12.23.4 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product Portfolio
  138. 12.23.5 Alexion Pharmaceuticals Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst